Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
DNP – Die Neurologie & Psychiatrie
Erschienen in: DNP - Der Neurologe & Psychiater 6/2014

29.05.2014 | Fortbildung

Wenn die Beine nicht mehr zur Ruhe kommen

Restless-Legs-Syndrom

verfasst von: Prof. Dr. med. Juliane Winkelmann, Dr. med. Nadine Groß

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Restless-Legs-Syndrom ist eine chronisch-progrediente Erkrankung mit sehr variabler klinischer Ausprägung von milden, intermittierenden und wenig belastenden Symptomen bis hin zu täglichen Beschwerden mit erheblichen Ein- und Durchschlafstörungen. Abhängig von der Ausprägung des Schweregrades benötigt aber nur ein kleiner Teil aller RLS-Patienten eine medikamentöse Therapie.
Literatur
1.
Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Archives of internal medicine. 2004;164(2):196–202.PubMedCrossRef
2.
Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology. 2000;54(5):1064–8.PubMedCrossRef
3.
Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Archives of internal medicine. 2005;165(11):1286–92.PubMedCrossRef
4.
Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep medicine. 2003;4(2):101–19.PubMedCrossRef
5.
Stiasny-Kolster K, Kohnen R, Moller JC, Trenkwalder C, Oertel WH. Validation of the „L-DOPA test“ for diagnosis of restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2006;21(9):1333–9.CrossRef
6.
Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Movement disorders: official journal of the Movement Disorder Society. 1997;12(1):61–5.CrossRef
7.
Schormair B, Kemlink D, Roeske D, Eckstein G, Xiong L, Lichtner P, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nature genetics. 2008;40(8):946–8.PubMedCrossRef
8.
Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nature genetics. 2007;39(8):1000–6.PubMedCrossRef
9.
Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep medicine. 2003;4(2):121–32.PubMedCrossRef
10.
Silber MH, Ehrenberg BL, Allen RP, Buchfuhrer MJ, Earley CJ, Hening WA, et al. An algorithm for the management of restless legs syndrome. Mayo Clinic proceedings Mayo Clinic. 2004;79(7):916–22.CrossRef
11.
Allen R, Becker PM, Bogan R, Schmidt M, Kushida CA, Fry JM, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27(5):907–14.PubMed
12.
Inoue YI, Hirata K, Kuroda K, Fujita M, Shimizu T, Emura N, et al. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study. Sleep Med. 2010 Jan;11(1):11–6.PubMedCrossRef
13.
Oertel WH, Benes H, Garcia-Borreguero D, Hogl B, Poewe W, Montagna P, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep medicine. 2010;11(9):848–56.PubMedCrossRef
14.
Inoue Y, Kuroda K, Hirata K, Uchimura N, Kagimura T, Shimizu T. Long-term open-label study of pramipexole in patients with primary restless legs syndrome. Journal of the neurological sciences. 2010;294(1–2):62–6.PubMedCrossRef
15.
Garcia-Borreguero D, Hogl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Movement disorders: official journal of the Movement Disorder Society. 2012;27(2):277–83.CrossRef
16.
Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, O’Keeffe S, Trenkwalder C, Hogl B, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. European journal of neurology: the official journal of the European Federation of Neurological Societies. 2012;19(11):1385–96.CrossRef
17.
Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Levodopa for restless legs syndrome. The Cochrane database of systematic reviews. 2011(2):CD005504.
18.
Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19(3):205–13.PubMed
19.
Hogl B, Garcia-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. Journal of neurology. 2010;257(2):230–7.PubMedCentralPubMedCrossRef
20.
Oertel W, Trenkwalder C, Benes H, Ferini-Strambi L, Hogl B, Poewe W, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet neurology. 2011;10(8):710–20.PubMedCrossRef
21.
Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep medicine. 2011;12(5):440–4.PubMedCrossRef
22.
Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. The Journal of clinical psychiatry. 1999;60(4):241–4.PubMedCrossRef
23.
Trenkwalder C, Benes H, Grote L, Garcia-Borreguero D, Hogl B, Hopp M, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet neurology. 2013;12(12):1141–50.PubMedCrossRef
24.
Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep. 1993;16(4):327–32.PubMed
25.
Walters AS, Winkelmann J, Trenkwalder C, Fry JM, Kataria V, Wagner M, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Movement disorders: official journal of the Movement Disorder Society. 2001;16(6):1105–9.CrossRef
26.
Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59(10):1573–9.PubMedCrossRef
27.
Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology. 2003;48(2):82–6.PubMedCrossRef
28.
Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep medicine. 2010;11(6):512–9.PubMedCrossRef
29.
Garcia-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M, Palacios JC, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010;74(23):1897–904.PubMedCrossRef
30.
Burke RA, Faulkner MA. Review of the treatment of restless legs syndrome: focus on gabapentin enacarbil. Journal of central nervous system disease. 2012;4:147–56.PubMedCentralPubMedCrossRef
31.
Ellenbogen AL, Thein SG, Winslow DH, Becker PM, Tolson JM, Lassauzet ML, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clinical neuropharmacology. 2011;34(1):8–16.PubMedCrossRef
32.
Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clinical neuropharmacology. 2012;35(4):165–73.PubMedCrossRef
33.
Winkelman JW, Bogan RK, Schmidt MH, Hudson JD, DeRossett SE, Hill-Zabala CE. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2011;26(11):2065–72.CrossRef
34.
Schulte EC, Gross N, Slawik H, Winkelmann J. When restless legs syndrome turns malignant. Sleep medicine. 2013;14(6):575–7.PubMedCrossRef
35.
O’Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age and ageing. 1994;23(3):200–3.PubMedCrossRef
36.
Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep. 1998;21(4):371–7.PubMed
37.
Frauscher B, Gschliesser V, Brandauer E, El-Demerdash E, Kaneider M, Rucker L, et al. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep medicine. 2009;10(6):611–5.PubMedCrossRef
38.
Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep medicine. 2008;9(5):572–4.PubMedCrossRef
39.
Leitlinien Restless Legs Syndrom (RLS) und Periodic Limb Movement Disorder (PLMD). Entwicklungsstufe S1, Stand September 2012. AWMF-Registernummer 030/081
40.
Earley CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep medicine. 2004;5(3):231–5.PubMedCrossRef
41.
Earley CJ, Heckler D, Allen RP. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep medicine. 2005;6(4):301–5.PubMedCrossRef
42.
Ondo WG. Intravenous iron dextran for severe refractory restless legs syndrome. Sleep medicine. 2010;11(5):494–6.PubMedCrossRef
43.
Auerbach M. Finding a safe and effective intravenous iron treatment for restless legs syndrome. Sleep medicine. 2010;11(5):429–30.PubMedCrossRef
44.
Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2009;24(10):1445–52.CrossRef
45.
Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep medicine. 2009;10(2):206–11.PubMedCentralPubMedCrossRef
46.
Vadasz D, Ries V, Oertel WH. Intravenous iron sucrose for restless legs syndrome in pregnant women with low serum ferritin. Sleep medicine. 2013;14(11):1214–6.PubMedCrossRef
47.
Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep medicine. 2011;12(9):906–13.PubMedCrossRef
48.
Oertel WH, Trenkwalder C, Zucconi M, Benes H, Borreguero DG, Bassetti C, et al. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2007;22 Suppl 18:S466–75.CrossRef
49.
Manconi M, Govoni V, De Vito A, Economou NT, Cesnik E, Casetta I, et al. Restless legs syndrome and pregnancy. Neurology. 2004;63(6):1065–9.PubMedCrossRef
50.
Manconi M, Ferini-Strambi L, Hening WA. Response to Clinical Corners case (Sleep Medicine 6/2: 83-4): Pregnancy associated with daytime sleepiness and nighttime restlessness. Sleep medicine. 2005;6(5):477–8.PubMedCrossRef
51.
Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. American journal of obstetrics and gynecology. 2011;204(4):314 e1–11.PubMedCrossRef
52.
Djokanovic N, Garcia-Bournissen F, Koren G. Medications for restless legs syndrome in pregnancy. Journal of obstetrics and gynaecology Canada: JOGC = Journal d’obstetrique et gynecologie du Canada: JOGC. 2008;30(6):505–7.PubMed
53.
Saletu M, Anderer P, Saletu-Zyhlarz G, Prause W, Semler B, Zoghlami A, et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2001;11(2):153–61.CrossRef
54.
Hurault-Delarue C, Montastruc JL, Beau AB, Lacroix I, Damase-Michel C. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Archives of gynecology and obstetrics. 2014.
55.
Fujii H, Goel A, Bernard N, Pistelli A, Yates LM, Stephens S, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology. 2013;80(17):1565–70.PubMedCentralPubMedCrossRef
56.
Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of neurology. 2014;261(3):579–88.PubMedCrossRef
57.
Merlino G, Gigli GL, Valente M. Sleep disturbances in dialysis patients. Journal of nephrology. 2008;21 Suppl 13:S66–70.PubMed
58.
Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2004;43(4):663–70.CrossRef
59.
Trenkwalder C, Stiasny K, Pollmacher T, Wetter T, Schwarz J, Kohnen R, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep. 1995;18(8):681–8.PubMed
60.
Pellecchia MT, Vitale C, Sabatini M, Longo K, Amboni M, Bonavita V, et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clinical neuropharmacology. 2004;27(4):178–81.PubMedCrossRef
61.
Miranda M, Kagi M, Fabres L, Aguilera L, Alvo M, Elgueta L, et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology. 2004;62(5):831–2.PubMedCrossRef
62.
Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2001;38(1):104–8.CrossRef
63.
de Oliveira MM, Conti CF, Valbuza JS, de Carvalho LB, do Prado GF. The pharmacological treatment for uremic restless legs syndrome: evidence-based review. Movement disorders: official journal of the Movement Disorder Society. 2010;25(10):1335–42.CrossRef
64.
Winkelmann J, Stautner A, Samtleben W, Trenkwalder C. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Movement disorders: official journal of the Movement Disorder Society. 2002;17(5):1072–6.CrossRef
65.
Garcia-Borreguero D, Stillman P, Benes H, Buschmann H, Chaudhuri KR, Gonzalez Rodriguez VM, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC neurology. 2011;11:28.PubMedCentralPubMedCrossRef
Metadaten
Titel
Wenn die Beine nicht mehr zur Ruhe kommen
Restless-Legs-Syndrom
verfasst von
Prof. Dr. med. Juliane Winkelmann
Dr. med. Nadine Groß
Publikationsdatum
29.05.2014
Verlag
Urban & Vogel
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 6/2014
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-014-0715-z

Weitere Artikel der Ausgabe 6/2014

DNP - Der Neurologe & Psychiater 6/2014 Zur Ausgabe

Fortbildung

Vertrauliche Geburt statt anonymer Geburt und Babyklappe

Pharmaforum

ADHS: An den Stärken der Patienten ansetzen

Literatur kompakt

Neurofeedback und Methylphenidat im Vergleich

Praxis konkret_Abrechnungstipps

Allgemeine Beratungen abrechnen

Kurz gemeldet

ADHS — Alternative zu MPH

Kurz gemeldet

BÄK-Leitfaden unterstützt beim Peer-Review

Neu in den Fachgebieten Neurologie und Psychiatrie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Bildnachweise